Date |
Product |
Disease |
Phase |
Company |
Therapeutic area |
2017-09-10
|
Keytruda® (pembrolizumab) |
locally advanced or metastatic urothelial carcinoma with disease progression on or after platinum-containing chemotherapy (post-platinum failure) |
3 |
Merck&Co (USA - NJ) |
Cancer - Oncology |
2017-09-09
|
lasmiditan |
migraine |
3 |
Eli Lilly (USA - IN) |
CNS diseases - Neurological diseases |
2017-09-09
|
Cabometyx™ (cabozantinib) |
previously untreated advanced renal cell carcinoma (RCC) |
2 |
Exelixis (USA - CA) |
Cancer - Oncology |
2017-09-09
|
epacadostat and Keytruda® (pembrolizumab) |
melanoma |
3 |
Incyte (USA - DE) Merck&Co (USA - NJ) |
Cancer - Oncology |
2017-09-08
|
pembrolizumab |
advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma |
2 |
Merck&Co (USA - NJ) |
Cancer - Oncology |
2017-09-08
|
tisotumab vedotin (HuMax-TF-ADC) |
solid tumors (ovarian cancer, cervical cancer, endometrium cancer, bladder cancer, prostate cancer, esophageal cancer, lung cancer) |
1-2 |
Genmab (Denmark) |
Cancer - Oncology |
2017-09-08
|
Ery-asp®/Graspa® (eryaspase - L-asparaginase loaded erythrocytes) |
pancreatic cancer |
2 |
Erytech Pharma (France) |
Cancer - Oncology |
2017-09-07
|
givosiran (ALN-AS1) |
hepatic porphyrias, including acute intermittent porphyria (AIP) |
1 |
Alnylam Pharmaceuticals (USA - MA) |
Rare diseases - Metabolic diseases |
2017-09-07
|
upadacitinib (ABT-494) |
atopic dermatitis |
2 |
Abbvie (USA - IL) |
Autoimmune diseases - Dermatological diseases |
2017-09-07
|
VK2809 |
glycogen storage disease type Ia (GSD Ia) |
preclinical |
Viking Therapeutics (USA - CA) |
Rare diseases - Genetic diseases - Liver diseases |
2017-09-07
|
IFX-1 |
moderate to severe Hidradenitis Suppurativa (HS) |
2a |
InflaRx (Germany) |
Dermatological diseases - Inflammatory diseases |
2017-09-06
|
AAI101 and cefepime |
complicated urinary tract infections (cUTI) |
2 |
Allecra Therapeutics (France - Germany) |
Infectious diseases |
2017-09-06
|
AllerT |
birch pollen allergy |
2b |
Anergis (Switzerland) |
Allergic diseases - Immunological diseases |
2017-09-06
|
PXS-5382A |
idiopathic pulmonary fibrosis (IPF) and other fibrotic conditions including non-alcoholic steatohepatitis (NASH), kidney fibrosis and heart fibrosis |
1 |
Synairgen (UK) |
Lung diseases - Respiratory diseases - Rare diseases - Fibrotic diseases |
2017-09-06
|
MTL-CEBPA - CEBPA-51 |
|
preclinical |
Mina Therapeutics (UK) |
Cancer - Oncology - Liver diseases - Hepatic diseases |
2017-09-06
|
DS-1211 |
|
1 |
Daiichi Sankyo (Japan) Sanford Burnham Prebys Medical Discovery Institute (USA - CA) |
|
2017-09-05
|
QGC001 |
arterial hypertension |
2 |
Quantum Genomics (France) |
Cardiovascular diseases |
2017-09-05
|
Arikayce® (amikacin sulfate - liposomal amikacin for inhalation) |
treatment-refractory Nontuberculous Mycobacterial (NTM) lung disease caused by Mycobacterium Avium Complex (M |
3 |
Insmed Limited (USA - NJ) |
Infectious diseases |
2017-09-05
|
B12019 - pegfilgrastim - biosimilar version of Neulasta® |
chemotherapy induced neutropenia |
1 |
Cinfa Biotech (Spain) |
Cancer - Oncology |
2017-09-05
|
B12019 - pegfilgrastim - biosimilar version of Neulasta® |
chemotherapy induced neutropenia. |
1 |
Cinfa Biotech (Spain) |
Cancer - Oncology |